La thérapie photodynamique en gastroentérologie: quoi de neuf en 2009 ?
Tóm tắt
Từ khóa
Tài liệu tham khảo
Craig C, Gray J, Macpherson M, et al. Porfimer sodium photodynamic therapy in the treatment of early esophageal cancer. Photodiagnosis and Photodynamic Therapy 2007;4:244–248.
Maunoury V, Mordon S, Bulois P, et al. Photodynamic therapy for early esophageal cancer. Dig Liver Dis 2005;37:491–495.
Lecleire S, Di Fiore F, Antonietti M, et al. Nonoperable patients with superficial esophageal cancer treated by photodynamic therapy after chemoradiotherapy have more severe complications than patients treated in primary intent. Am J Gastroenterol 2008;103:2215–2219.
Rastogi A, Puli S, El-Serag HB, et al. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 2008;67:394–398.
Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofr in in Barrett’s high-grade dysplasia. Gastrointest Endosc 2007;66:460–468.
Hernandez JC, Reicher S, Chung D, et al. Pilot series of radiofrequency ablation of Barrett’s esophagus with or without neoplasia. Endoscopy 2008;40:388–392.
Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003;125:1355–1363.
Cheon YK, Cho YD, Baek SH, et al. Comparison of survival of advanced hilar cholangiocarcinoma after biliary drainage alone versus photodynamic therapy with external drainage. Korean J Gastroenterol 2004;44:280–287.
Zoepf T, Jakobs R, Arnold JC, et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005;100:2426–2430.
Boyer J, Maunoury V, Quentin V, et al. Results of a multicenter open study of photodynamic therapy in 49 patients with cholangiocarcinoma. UEGW Paris 2007. Gut 2007;56(Suppl III):A9.
Wiedmann M, Berr F, Schiefke I, et al. Photodynamix therapy in patients with non — resectable hilar cholangiocarcinomas: 5 year follow — up of a prospective phase II study. Gastrointest Endosc 2004;60:68–75.
Witzigmann H, Berr F, Ringel U, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg 2006;244:230–239.
Wang L W, Li LB, Li ZS, et al. Self-expandable metal stents and trans-stent light delivery: are metal stents and photodynamic therapy compatible? Lasers Surg Med 2008;40:651–659.
Baisden JM, Kahaleh M, Weiss GR, et al. Multimodality Treatment with Helical Tomotherapy Intensity Modulated Radiotherapy, Capecitabine, and Photodynamic Therapy is Feasible and Well Tolerated in Patients with Hilar Cholangiocarcinoma. Gastrointest Cancer Res 2008;2:219–224.
Prasad GA, Wang KK, Baron TH, et al. Factors associated with increased survival after photodynamic therapy for cholangiocar cinoma. Clin Gastroenterol Hepatol 2007;5:743–748.
Kahaleh M, Mishra R, Shami VM, et al. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin Gastroenterol Hepatol 2008;6:290–297.
Henderson BW, Busch TM, Vaughan LA, et al. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluencerate. Cancer Res 2000;60:525–529.
Mordon S, Maunoury V. Using white light during photodynamic therapy: visualization only or treatment? Eur J Gastroenterol Hepatol 2006;18:765–771.
Allison RR, Sibata CH. Photofrin photodynamic therapy: 2.0 mg/kg or not 2.0 mg/kg that is the question. Photodia gnosis Photodyn Ther 2008;5:112–119.